MannKind Corporation to Hold 2021 Second Quarter Financial Results Conference Call on August 11, 2021
August 04 2021 - 6:15AM
MannKind Corporation (Nasdaq:MNKD) will release
its 2021 second quarter financial results and its management will
host a conference call to discuss the financial results and
corporate updates at 5:00 PM (Eastern Time) on Wednesday, August
11, 2021.
Presenting from the Company will be its Chief Executive Officer,
Michael Castagna and Chief Financial Officer, Steven B. Binder.
Those interested in listening to the conference call live via
the Internet may do so by visiting the Company's website at
https://investors.mannkindcorp.com/events-and-presentations Events
& Presentations. A replay will also be available on
MannKind's website for 14 days.
About MannKind Corporation MannKind Corporation
(Nasdaq: MNKD) focuses on the development and commercialization of
inhaled therapeutic products for patients with endocrine and orphan
lung diseases. MannKind is currently commercializing Afrezza®
(insulin human) Inhalation Powder, the Company’s first FDA-approved
product and the only inhaled ultra-rapid-acting mealtime insulin in
the United States, where it is available by prescription from
pharmacies nationwide. Afrezza is also available by prescription in
Brazil where it is commercialized by the Company’s partner Biomm
SA. MannKind was established in 1991, and is headquartered in
Westlake Village, Calif., with a manufacturing and R&D facility
in Danbury, Conn. The Company also employs field sales and medical
representatives across the U.S. Please visit www.mannkindcorp.com
to learn more.
MANNKIND CONTACT:Rose Alinaya, Investor
Relations Phone: (818) 661-5000 Email: ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jun 2024 to Jul 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jul 2023 to Jul 2024